Mismatch-based delayed thrombolysis: a meta-analysis by Mishra, N.K. et al.
 
 
 
 
 
 
 
Mishra, N.K., Donnan, G.A., Furlan, A.J., Hacke, W., and Lees, 
K.R. (2010) Mismatch-based delayed thrombolysis: a meta-
analysis. Stroke, 41 (1). e25-e33. ISSN 0039-2499 
 
 http://eprints.gla.ac.uk/25902/ 
 
Deposited on: 18 January 2012 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Anthony J. Furlan, Werner Hacke and Kennedy R. Lees
Nishant K. Mishra, Gregory W. Albers, Stephen M. Davis, Geoffrey A. Donnan,
Mismatch-Based Delayed Thrombolysis : A Meta-Analysis
ISSN: 1524-4628 
Copyright © 2009 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online
Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
doi: 10.1161/STROKEAHA.109.566869
2010, 41:e25-e33: originally published online November 19, 2009Stroke 
 http://stroke.ahajournals.org/content/41/1/e25
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://stroke.ahajournals.org/http://stroke.ahajournals.org/content/41/4/e399.full.pdf
 An erratum has been published regarding this article. Please see the attached page for: 
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://stroke.ahajournals.org//subscriptions/
Subscriptions: Information about subscribing to Stroke is online at 
 at GLASGOW UNIV LIB on January 18, 2012http://stroke.ahajournals.org/Downloaded from 
Mismatch-Based Delayed Thrombolysis
A Meta-Analysis
Nishant K. Mishra, MBBS; Gregory W. Albers, MD; Stephen M. Davis, MD, FRACP;
Geoffrey A. Donnan, MD, FRACP; Anthony J. Furlan, MD;
Werner Hacke, MD; Kennedy R. Lees, MD, FRCP
Background and Purpose—Clinical benefit from thrombolysis is reduced as stroke onset to treatment time increases. The
use of “mismatch” imaging to identify patients for delayed treatment has face validity and has been used in case series
and clinical trials. We undertook a meta-analysis of relevant trials to examine whether present evidence supports delayed
thrombolysis among patients selected according to mismatch criteria.
Methods—We collated outcome data for patients who were enrolled after 3 hours of stroke onset in thrombolysis trials and
had mismatch on pretreatment imaging. We selected the trials on the basis of a systematic search of the Web of
Knowledge. We compared favorable outcome, reperfusion and/or recanalization, mortality, and symptomatic intrace-
rebral hemorrhage between the thrombolyzed and nonthrombolyzed groups of patients and the probability of a favorable
outcome among patients with successful reperfusion and clinical findings for 3 to 6 versus 6 to 9 hours from poststroke
onset. Results are expressed as adjusted odds ratios (a-ORs) with 95% CIs. Heterogeneity was explored by test statistics
for clinical heterogeneity, I2 (inconsistency), and L’Abbé plot.
Results—We identified articles describing the DIAS, DIAS II, DEDAS, DEFUSE, and EPITHET trials, giving a total of
502 mismatch patients thrombolyzed beyond 3 hours. The combined a-ORs for favorable outcomes were greater for
patients who had successful reperfusion (a-OR5.2; 95% CI, 3 to 9; I20%). Favorable clinical outcome was not
significantly improved by thrombolysis (a-OR1.3; 95% CI, 0.8 to 2.0; I220.9%). Odds for reperfusion/recanalization
were increased among patients who received thrombolytic therapy (a-OR3.0; 95% CI, 1.6 to 5.8; I225.7%). The
combined data showed a significant increase in mortality after thrombolysis (a-OR2.4; 95% CI, 1.2 to 4.9; I20%),
but this was not confirmed when we excluded data from desmoteplase doses that were abandoned in clinical
development (a-OR1.6; 95% CI, 0.7 to 3.7; I20%). Symptomatic intracerebral hemorrhage was significantly
increased after thrombolysis (a-OR6.5; 95% CI, 1.2 to 35.4; I20%) but not significant after exclusion of abandoned
doses of desmoteplase (a-OR5.4; 95% CI, 0.9 to 31.8; I20%).
Conclusions—Delayed thrombolysis amongst patients selected according to mismatch imaging is associated with
increased reperfusion/recanalization. Recanalization/reperfusion is associated with improved outcomes. However,
delayed thrombolysis in mismatch patients was not confirmed to improve clinical outcome, although a useful clinical
benefit remains possible. Thrombolysis carries a significant risk of symptomatic intracerebral hemorrhage and possibly
increased mortality. Criteria to diagnose mismatch are still evolving. Validation of the mismatch selection paradigm is
required with a phase III trial. Pending these results, delayed treatment, even according to mismatch selection, cannot
be recommended as part of routine care. (Stroke. 2010;41:e25-e33.)
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Thrombolysis is the principal therapy for acute strokepatients in the early hours after symptom onset1–3 but has
a short treatment window. In a meta-analysis of data derived
from 2775 patients (pooled from the ATLANTIS, ECASS,
and NINDS trials), there was a gradually diminishing benefit
toward 6 hours from stroke onset [(odds ratio [OR]2.8; 95%
CI, 1.8 to 4.5) for 0 to 90 minutes, 1.6 (95% CI, 1.1 to 2.2)
for 91 to 180 minutes, 1.4 (95% CI, 1.1 to 1.9) for 181 to 270
minutes, and 1.2 (95% CI, 0.9 to 1.5) for 271 to 360
minutes].4 Recently, the ECASS III trial (N821; treatment
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vs placebo 1:1; median time for administration of alte-
plase3 hours, 59 minutes) confirmed clinical benefit within
4.5 hours of stroke onset. (OR1.34; 95% CI, 1.02 to 1.76;
P0.04).4 However, the wider 95% CI at 6 hours (0.9 to 1.5
for 271 to 360 minutes in the meta-analysis4) have suggested
that there may still be patients able to benefit from
thrombolysis even beyond 4.5 hours. Conversely, others may
be at increased risk from late treatment. The use of imaging
approaches to select patients who have remaining salvageable
tissue for delayed treatment has been proposed, most notably
approaches that include magnetic resonance imaging (MRI)
perfusion/diffusion “mismatch.”5,6 Several trials have tested
thrombolysis in patients selected after MRI; some centers
have also incorporated mismatch imaging and delayed
thrombolysis into their routine clinical practice.7 We under-
took a meta-analysis of data in the public domain to examine
whether extension of the treatment window among patients
selected according to the presence of mismatch can be
recommended for routine clinical practice.
Methods
Selection of Trials
We planned to include only relevant articles that described the
findings of studies that either undertook prospective enrollment of
consecutive stroke patients with a mismatch profile suitable for
delayed thrombolysis (beyond 3 hours of stroke onset) or had studied
mismatch-based, delayed thrombolysis in a randomized controlled
design. We excluded case reports, case series, and studies restricted
to specific anatomic brain locations.8 We defined the (1) mismatch
profile as a perfusion volume at least 1.2 times that of the infarct core
with use of the imaging methodology available at the specific trial
center, (2) symptomatic intracerebral hemorrhage (SICH) as a
radiologically confirmed cerebral hemorrhage in association with
clinical worsening after thrombolytic therapy (within 36 hours in the
case of therapy with recombinant tissue-type plasminogen activator
[rt-PA] and 72 hours in the case of therapy with desmoteplase), (3)
reperfusion and/or recanalization according to the respective studies’
definitions, (4) favorable clinical outcome as a National Institutes of
Health Stroke Scale (NIHSS) improvement of 8 points from baseline
or attainment of an NIHSS score of 0 or 1 and/or a modified Rankin
Scale score of 0 or 1, and (5) mortality as death (Rankin Scale score
of 6) in the 90 days after thrombolytic therapy. We considered rt-PA
and desmoteplase together because both are thrombolytic agents.9
They differ in some features: desmoteplase lacks the second kringle
site in its molecular structure, does not need to be cleaved by
plasmin, is active in its single-chain form, has reduced neurotoxicity,
and has limited passage through the blood-brain barrier. Desmote-
plase has a theoretical advantage over rt-PA because the former is
almost nonfunctional when fibrin is absent.9–15 Alteplase is already
a proven therapy for treating stroke patients within the early hours
after stroke onset (NINDS16 and ECASS III3).17 Doses that have
acceptable safety and efficacy have been identified.18–20 Both
desmoteplase and alteplase remain investigational for delayed
thrombolysis. However, we undertook a sensitivity analyses for any
differential effect between desmoteplase and alteplase.
Until the DIAS II study, identification of the ischemic penumbra
was based on the mismatch between MRI perfusion-weighted
imaging and diffusion-weighted imaging.18 For the first time, the
DIAS II investigators were permitted to select patients on the basis
of visual inspection of the mismatch on perfusion computed tomog-
raphy (CT) images as an alternative to MRI perfusion studies,
depending on the local expertise of the imaging center. We included
data from either method as reported in the DIAS II publication.18
We included all trials that defined the mismatch profile as the
perfusion volume being 1.2 times the infarct core. We placed no
restriction on the manner in which perfusion was measured in these
trials. For example, in DIAS II, the mismatch population was
identified on the basis of either CT perfusion or MRI perfusion,
according to center preference. The determination of mismatch in
DEFUSE and EPITHET trials was based on postprocessed
perfusion-weighted imaging data that included correction for arterial
input and thresholding. In contrast, in the desmoteplase studies,
mismatch was determined in “real time,” without postprocessing, by
the investigator using the “eyeball” technique.
End Points
End points of interest for our meta-analysis were comparisons
between thrombolyzed and nonthrombolyzed patients in (1) favor-
able outcome, (2) reperfusion and/or recanalization, (3) mortality,
and (4) SICH. We also examined the rates of favorable versus
unfavorable clinical outcome amongst successfully reperfused
patients.
Search
We first searched the Web of Knowledge for 10 broad terms:
“clinical trial*,” “prospective study,” “stroke trial*” “thrombolytic
agent,” “desmoteplase,” “tissue plasminogen activator,” “recanaliza-
tion in stroke,” “ reperfusion therapy in stroke,” “penumbra in
stroke,” and “mismatch hypotheses.” Then we refined our search by
combining these with terms that underline the mismatch hypotheses
and thrombolysis. Our last search was undertaken on March 1, 2009.
From a review of the title and abstract, we selected for further
examination all relevant articles describing the original findings of
studies that used the mismatch hypotheses and selected patients for
thrombolysis despite delay beyond 3 hours of stroke onset. We
checked whether any later article or abstract offered supplemental
data. Once selected, each article was read completely and the
relevant data extracted. We also searched the bibliography of each of
these articles for additional articles.
Statistical Analysis
For this meta-analysis, we retrieved “estimate(s) of effect” from the
abstract(s). When relevant data were missing, we searched the full
text and any supplementary articles.21 Primarily, we wished to
analyze data derived from the patients with a mismatch profile on an
intention-to-treat basis, but when intention-to-treat data were un-
available, we accepted “per protocol” data and described the under-
lying limitations. Our comparisons were mainly planned between
patients offered any dose of any thrombolytic agent and the corre-
sponding placebo-treated patients.
We performed subgroup analyses amongst patients who were
treated with thrombolytics at doses approved or still under clinical
investigation, ie, 90 g/kg desmoteplase or 0.9 mg/kg rt-PA.
Comparisons (summary estimates) are expressed as ORs and their
95% CIs. Whereas we applied both fixed (inverse-variance weight-
ing method) and random (adjusted OR [a-OR]21) methods to calcu-
late the summary estimate, we reported only the findings of the fixed
method but have indicated the instances where the results diverged.
We assessed the heterogeneity with the test statistics for heteroge-
neity and I2 for inconsistency supported by examination of L’Abbé
plots.
Our analysis included data derived from those patients who were
selected (or could have been selected) on the basis of their mismatch
profile. To assess whether favorable outcomes (clinical outcomes at
day 90) were more common amongst patients who had successful
reperfusion, we retrieved data on 242 patients for whom the
reperfusion findings were available (the DIAS I trial, N9720; the
DEDAS trial, N3419; the EPITHET trial, N77 [“good neurolog-
ical outcome” for patients with {n30} and without {n47}
reperfusion in mismatch patients only]22; and the DEFUSE trial,
N34, in mismatch patients with [n18] and without [n16] early
reperfusion23). Corresponding information was not reported in the
DIAS II trial.18 Similarly, to answer whether a favorable clinical
outcome occurred more frequently in the thrombolyzed group of
patients, information on 410 patients was available (DIAS I,
N10220; DIAS II, N18618; DEDAS, N3719; and EPITHET,
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N85; mismatch patients with and without good neurological
outcome in the thrombolysis group, n42, and the placebo group,
n4322) for those patients who received any thrombolytic agent at
any dosage. Next, to answer whether reperfusion or recanalization
occurred more frequently amongst those who were thrombolyzed,
we retrieved data on 211 patients who received thrombolytic therapy
at any dose (DIAS I, 97 patients20; DEDAS, intention to treat 37
patients19 and target population 23 patients; and EPITHET, 77
patients22). To assess mortality between thrombolyzed and non-
thrombolyzed patients, we extracted data on 410 patients (DIAS I,
102 patients20; DIAS II, 186 patients18; DEDAS, 37 patients19; and
EPITHET, 85 mismatch only patients22). To assess SICH between
thrombolyzed and nonthrombolyzed patients, we extracted data on
405 patients (DIAS I, 102 patients20; DIAS II, 186 patients18;
DEDAS, 37 patients 19; and EPITHET, 80 mismatch patients only22).
Owing to mathematical difficulties involved in calculating OR when
the numerator is zero, we combined the DEDAS data with DIAS I
data for mortality analysis.
We undertook sensitivity (subgroup) analyses in which we com-
pared the data after excluding the data for those who received doses
of desmoteplase that were abandoned for further evaluation. We also
analyzed differences in clinical outcome between the patients who
were thrombolyzed within 3 to 6 hours of stroke onset versus those
who were thrombolyzed beyond 6 hours. Finally, we compared and
contrasted the attributes of the studies and assessed their quality on
the basis of the manner in which patients were enrolled and the
resulting baseline characteristics.
Results
Literature Search
The literature search led to 13 citations on the DEFUSE
trial (10 articles)23–32, 2 on the DEDAS trial (1 article19),
6 on the DIAS trial20,30, 9 on the EPITHET trial (8
articles20,22,33–36), and 2 on DIAS II (1 article).37 Information
on 502 patients was obtained from the 5 main articles
describing the relevant trials (DIAS, 104 patients20; DIAS II,
186 patients18; DEDAS, 37 patients19; DEFUSE, 74 patients23;
and EPITHET, 101 patients22), and the data corresponding to
patients with a mismatch profile were retrieved for subsequent
analysis.
Comparative Analysis of the Mismatch Trials
We compared the attributes that differed between trials to
highlight the underlying heterogeneity in the manner in which
the selected trials were conducted (Supplemental Table I
available online at http://stroke.ahajournals.org). DIAS II18
enrolled the least severely affected stroke patients (median
NIHSS score9) and EPITHET,22 the most severely affected
(median NIHSS score14 in the treatment arm and 10 in the
placebo arm). Median baseline NIHSS scores were 11.5 and
12, respectively, in the DEFUSE23 and DIAS I20 trials. We
also compared the time since stroke onset until thrombolysis
(OTT), and we assessed qualitatively the proportion of
patients treated in each trial after 4.5 hours (Supplemental
Table II, available online at http://stroke.ahajournals.org).
Detailed analysis of OTT could not be undertaken without
raw data.
Findings From Statistical Analyses
Did Reperfusion or Recanalization Occur More
Frequently in Patients Who Were Thrombolyzed?
The data from 211 patients showed greater individual odds
for reperfusion and/or recanalization amongst those who
received thrombolytic therapy in: DIAS I20 (OR4.1; 95%
CI, 1.3 to 15.2) and EPITHET (OR3.7; 95% CI, 1.3 to
10.8). Odds were nonsignificant in the DEDAS trial19
(OR0.9; 95% CI, 0.1 to 6.9). The combined data gave a
greater adjusted odds for reperfusion/recanalization for the
patients who had thrombolytic therapy at any dosage
(a-OR3.0; 95% CI, 1.6 to 5.8; P0.05, P for heteroge-
neity0.26, and I225.7%; Figure 1a).
We repeated our analysis after excluding desmoteplase
doses that were abandoned for clinical development; the
subanalysis restricted to 90 g/kg desmoteplase or rt-PA
gave an a-OR2.65 and a 95% CI of 1.3 to 5.5 (P0.007
fixed method; Figure 1b) and an a-OR2.28 and a 95% CI
of 0.7 to 7.3 (P0.17 random method; Figure 1c) (P for
clinical heterogeneity0.13, and I250.5%). We also
examined the underlying heterogeneity by L’Abbé plot
(Figures 2a and 2b).
Are Favorable Outcomes More Common in Patients Who
Underwent Reperfusion?
The individual odds for a favorable clinical outcome in the 4
studies reporting this end point were greater in patients who
underwent reperfusion compared with those who did not
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Figure 1. Did reperfusion or recanalization occur more fre-
quently in patients who were thrombolyzed? Findings are shown
from the fixed-method analysis of combined data (a) after exclu-
sion of abandoned doses by fixed (b) and random-method (c)
analyses.
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(DIAS I20 OR3.4; 95% CI, 1.3 to 8.8; DEDAS19 OR9.6;
95% CI, 1.5 to 64.6; EPITHET22 OR7.2; 95% CI, 2.3 to
23.2; and DEFUSE23 OR5.4; 95% CI, 0.94 to 38.1). For all
trials combined, the a-ORs were greater for patients who had
successful reperfusion compared with those who did not
(a-OR5.2; 95% CI, 3 to 9.1; P for clinical heterogene-
ity0.60; I20%; Figure 3a).
In a sensitivity analyses in which DEFUSE23 trial data
were excluded (as DEFUSE,23 unlike others, was a nonran-
domized, prospectively conducted study), the a-OR remained
greater among patients with successful reperfusion (a-
OR5.2; 95% CI, 2.8 to 9.5; P0.00; heterogeneity statistics
P0.4; I20%; Figure 3b).
Did a Favorable Clinical Outcome Occur More
Frequently in the Thrombolyzed Group of Patients?
With the exception of DIAS II,18 all trials reported nonsig-
nificantly improved odds of a favorable clinical outcome in
the thrombolysis group of patients: DIAS I20 OR2.2; 95%
CI, 0.7 to 7.4; DEDAS19 OR2.4; 95% CI, 0.4 to 28.0;
EPITHET22 OR1.7; 95% CI, 0.7 to 4.4; and DIAS II18
OR0.8; 95% CI, 0.4 to 1.6. The combined data analysis
failed to show a significant benefit (a-OR1.28; 95% CI,
0.84 to 1.97; P for clinical heterogeneity0.28; I220.9%;
Figure 4a). After exclusion of DIAS II data, a-OR was 1.96,
95% CI was 1.06 to 3.63, and for clinical heterogeneity, I2
was 0% and P was 0.89 (Figure 4b).
We repeated our analysis after excluding desmoteplase
doses that were abandoned for clinical development: with 90
g/kg desmoteplase and rt-PA 0.9 mg/kg data alone, we
found a-OR1.4; 95% CI, 0.9 to 2.3, P0.16; for clinical
heterogeneity, P0.56 and I20%. After exclusion of DIAS
II data, OR1.88; 95% CI, 0.95 to 3.72, and heterogeneity
Figure 2. Did reperfusion or recanalization
occur more frequently in patients who
were thrombolyzed? L’Abbé plot examin-
ing (a) the complete data set and (b) the
abandoned doses excluded for heteroge-
neity. The circle size denotes the sample
size; DIAS, gray circles; DEDAS open
circles; and EPITHET, black circles.
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Figure 3. Are favorable outcomes more common in patients
who underwent reperfusion? Findings are shown from the
fixed-method analysis of combined data (a) and after excluding
DEFUSE data (b).
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Figure 4. Did a favorable clinical outcome occur more fre-
quently in the thrombolyzed group of patients? Findings are
shown from the fixed-method analysis of combined data (a),
after exclusion of DIAS II data (b), and after exclusion of aban-
doned doses (c).
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statistics I20% and P0.69 (Figure 4c). L’Abbé plots were
examined for underlying heterogeneity in these analyses
(Figure 5). Under sensitivity analysis, no differential effect of
desmoteplase versus alteplase was found, with the ratio of
OR0.7 (95% CI, 0.24 to 1.92; P0.46).
Was There a Greater Probability of Mortality
in Thrombolyzed Compared With
Nonthrombolyzed Patients?
Here, the individual odds for mortality were nonsignificant in
the thrombolysis group: DIAS II18 OR2.4; 95% CI, 0.7 to
10.1; DIAS I OR3.6; 95% CI, 0.5 to 161.3; EPITHET22
OR2.7; 95% CI, 0.8 to 10.9; and DEDAS19 OR0.5; 95%
CI, 0.0 to 34.9. The combined data analysis found a signifi-
cant increase in mortality in the thrombolysis group of
patients compared with the placebo group (a-OR2.4; 95%
CI, 1.2 to 4.9; P0.02; P for heterogeneity0.67; and
I20%; Figure 6a).
Repeating our analysis after excluding data from the
abandoned desmoteplase doses, ie, restricting the analysis to
patients treated with 90 g/kg desmoteplase or 0.9 mg/kg
rt-PA, we found a-OR1.6; 95% CI, 0.7 to 3.7; P0.28; P
for heterogeneity0.56; and I20% (Figure 6b). Under
sensitivity analysis, no differential effect of desmoteplase
versus alteplase was found, with the OR0.8 (95% CI, 0.2 to
3.5; P0.8).
Was There a Greater Probability of SICH
in Thrombolyzed Compared With
Nonthrombolyzed Patients?
The individual odds for SICH were nonsignificant: DIAS I
OR7.9; 95% CI, 0.7 to infinity; DIAS II OR5.9; 95% CI,
0.5 to infinity; and EPITHET OR152.6; 95% CI, 15.9 to
infinity; but the combined odds for SICH were significantly
greater for the group that underwent thrombolytic therapy
(a-OR24.7; 95% CI, 5.2 to 118.2; heterogeneity statistics
I235.4% and P0.2; Figure 7a). After we combined data
from DEDAS with DIAS I, the findings remained nonsignif-
icant for the individual odds (DIAS IDEDAS OR7.1;
95% CI, 0.7 to infinity) but were significant for the combined
analysis (a-OR6.5; 95% CI, 1.2 to 35.4, and for clinical
heterogeneity, P1.0 and I20%; Figure 7b).
Repeating the analysis by excluding the data associated
with abandoned thrombolytic doses, the findings were non-
significant for both individual odds (DIAS IDEDAS
OR3.7; 95% CI, 0.03 to infinity; DIAS II OR5.7; 95% CI,
0.2 to infinity; and EPITHET OR6.5; 95% CI, 0.4 to
infinity) and in combination a-OR5.4; 95% CI, 0.9 to 31.8;
P for heterogeneity0.97; and I20% (Figure 7c) but at-
tained marginal significance of the adjusted odds derived
by considering the DIAS I and DEDAS data separately
(a-OR6.0; 95% CI, 1.00 to 35.8; heterogeneity statistics
P1.00 and I20%). There were no SICH occurrences in
the placebo arms, and therefore, a sensitivity analysis to
assess any differential effect of desmoteplase versus alte-
plase could not be undertaken.
Were There Better Clinical Findings (Outcomes or
Reperfusion) When Treatment Was Commenced Within 3
to 6 Hours Versus 6 to 9 Hours?
Limited data were available to examine OTT, and neither
DIAS I20 nor DIAS II individually suggested significantly
greater odds (DIAS I OR1.07; 95% CI, 0.4 to 2.9; P0.9;
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Figure 5. Did a favorable clinical outcome
occur more frequently in the thrombo-
lyzed group of patients? L’Abbé plot
examining heterogeneity in the analysis (a)
for complete data, (b) for DIAS II data
excluded, (c) for complete data but aban-
doned doses excluded, and (d) for DIAS II
data and abandoned-dose data excluded.
The size of the square denotes the sam-
ple size. 1 indicates DEDAS; 2, DIAS I; 3,
EPITHET; and 4, DIAS II (black rectangle).
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DIAS II OR0.8; 95% CI, 0.4 to 1.8; P0.7). With the data
from both trials combined, the a-OR0.9; 95% CI, 0.5 to 1.7,
and P0.8 (Figure 8).
Analysis of Mortality
In DIAS I, 1 placebo and 2 desmoteplase deaths occurred due
to cardiac causes. In the DIAS II trial, only 1 of 3 deaths in
the 90 g/kg group and 3 of 14 deaths in the 125 g/kg group
were considered related to the trial medication. In the
DEDAS trial, the sole death in the 90 g/kg group was due to
aspiration pneumonia, whereas that in the 125 g/kg groups
was due to evolving neurologic deterioration of a left middle
cerebral artery infarct, leading to pneumonia.
Discussion
We undertook a meta-analysis of all previous studies that
evaluated the principle of physiologic selection for delayed
thrombolysis, based on the presence of potentially viable
tissue in the ischemic penumbra.38,39 These trials used the
mismatch hypothesis with either MRI (perfusion/diffusion
mismatch) or CT (perfusion/cerebral blood volume mismatch)
as a signature of the putative penumbra.19,20,22,24,25,40–43 Apart
from the recent DIAS II trial,18 these trials had supported the
physiologic basis of the mismatch concept. The disappointing
findings of the DIAS II trial have been attributed to limita-
tions of the study and to chance.37 To test for consistency, we
undertook a meta-analysis of the studies that studied the
mismatch hypothesis to select and thrombolyze patients
despite delays beyond 3 hours. Five trials, DIAS I,20 DIAS
II,18 EPITHET,22 DEFUSE,23 and DEDAS,19 were available
for inclusion. Our results indicate that reperfusion/recanali-
zation is more common with thrombolysis when all doses are
considered together, but the significance was lost with the
exclusion of data for abandoned doses, which reduced the
power of our analysis through effects on sample size. Fur-
thermore, a favorable clinical outcome was more common
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Figure 6. Was there a greater probability of mortality in throm-
bolyzed patients compared with those not thrombolyzed? Find-
ings are shown from the fixed-method analysis of combined
data (a) and after exclusion of the abandoned-dose data (b).
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Figure 7. Was there a greater probability of SICH in thrombolyzed
patients compared with those not thrombolyzed? Findings are
shown from the fixed-method analysis for all studies combined but
with DEDAS data excluded (a), DEDAS combined with DIAS I data
(b), and after exclusion of the abandoned-dose data (c).
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Figure 8. Were there better clinical findings (outcomes or reper-
fusion) when treatment was commenced within 3 to 6 hours vs
6 to 9 hours?
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amongst patients with successful reperfusion of the ischemic
parenchyma, despite delays beyond 3 hours from stroke
onset. This conclusion was not influenced by inclusion of the
nonrandomized DEFUSE trial23 data. The DIAS II trial18 did
not report reperfusion findings.
However, we did not find evidence that a favorable clinical
outcome was significantly improved in the group that under-
went thrombolysis. Neither did we find a significant benefit
when we excluded doses of desmoteplase that were aban-
doned for clinical development. The CI around our estimate
of effect remains wide and would be consistent with a
doubling of odds for a favorable outcome, although in this
respect, DIAS II suggests that the likely upper limit may be
1.6. Even so, odds of 1.6 remain greater than those achieved
in unselected patients treated with rt-PA in the ECASS III
trial3 and have been regarded as sufficient to influence
national and European stroke treatment guidelines (SIGN44
and ESO45).
Late treatment, even amongst selected patients, may carry
some risk. We found a marginally significant increase in the
odds of death among all treated patients, with a point estimate
of 2.4. When we restricted the analysis to 0.9 mg/kg rt-PA
and to the dose of desmoteplase that remains under develop-
ment (90 g/kg), the OR for mortality fell to 1.6 and the risk
was nonsignificant. Higher doses of desmoteplase were
clearly linked to excessive SICH and were abandoned for this
reason. Our analysis did not take into account the attributed
cause of death. Many deaths in DIAS II and EPITHET were
considered unrelated to treatment. The attribution may be
important for understanding the mechanism of effect, but
caution is required when drawing conclusions from subjec-
tive assessments such as these. Treatment failure can contrib-
ute to late death, just as unrecognized excitotoxic damage
may represent a potential mechanism. Regardless, if mortality
is increased, this may be mediated via hemorrhagic
transformation.
Despite a lack of significance in the individual odds for
SICH in patients given thrombolytic therapy, the a-OR
indicated a statistically significant increase in SICH after
delayed thrombolysis. Similarly, an increased risk of SICH
has long been recognized for time-based t-PA in the estab-
lished clinical windows, but this is offset by the improved
clinical outcomes in treated patients. After exclusion of doses
of desmoteplase that were abandoned for clinical develop-
ment,20 the adjusted odds for SICH again lost significance.
Caution is required in interpreting these post hoc subgroup
analyses. Although the inclusion of data from all doses may
give a falsely pessimistic view of the risk/benefit profile after
mismatch-based thrombolysis, post hoc exclusion of doses
that were abandoned in clinical development is a data-driven
decision and raises statistical concerns of bias that can only be
assuaged by further prospective trials. We found no evidence
that relatively earlier (3- to 6-hour) versus later (6- to 9-hour)
treatment influenced our findings. This is particularly rele-
vant, because ECASS III has recently shown that unselected
patients benefit from alteplase given within 4.5 hours of
stroke onset, and a small proportion of patients in the
mismatch trials would now be considered eligible for such
treatment. We cannot exclude the possibility that some of the
potential benefit among mismatch patients may be time
dependent, but it appears unlikely that this is sufficient to
explain all effects. Now that the ECASS III results have been
presented, another meta-analysis of individual patient data
from the trials studied herein should be undertaken to assess
clinical and radiologic outcomes for patients who were
thrombolyzed beyond 4.5 hours of stroke onset. Similarly, an
additional analysis comparing outcomes in patients with
mismatch versus those without mismatch is desirable but was
beyond the scope of our meta-analysis.
Our meta-analysis included data from 5 different
trials,18–20,22–23 of which DEFUSE23 could be considered only
in the analysis of a favorable clinical outcome among patients
with reperfusion versus no reperfusion. DIAS II18 did not
report reperfusion findings and had to be excluded where
these data were needed. The L’Abbé plot46,47 suggested that
DIAS II18 contributed to the heterogeneity in the combined
analysis of favorable outcomes in all thrombolyzed patients,
and the DEDAS trial contributed to the heterogeneity in the
analysis of reperfusion and recanalization in patients throm-
bolyzed with the abandoned doses excluded. Both sources of
heterogeneity appeared to affect the results by virtue of the
effects of sample size on the power of a study.
We know that the number needed to treat to achieve an
enhanced favorable outcome with alteplase may be as few as
7 within 3 hours, but this number has risen by 3 to 4.5 hours
to 14.3 When treatment with alteplase is started within 6
hours OTT, the number needed to treat rises to 25.48 Hence,
our challenge is to identify those patients most likely to
benefit from delayed thrombolysis. The use of either MRI to
identify perfusion/diffusion mismatch or a CT-based alterna-
tive is attractive. It is clear from our data that delayed
thrombolysis among patients selected according to mismatch
imaging is associated with increased reperfusion/recanaliza-
tion and that recanalization/reperfusion is associated with
improved outcomes. At present, although the data remain
consistent with improved functional outcome from delayed
thrombolysis among mismatch patients, a statistically signif-
icant benefit on functional outcomes has not been confirmed.
Although our pooled results suggest that mortality may be
higher, the retention of excessive doses of desmoteplase in
the analysis is likely to lead to overestimation of any risk.
We note that existing methods for defining mismatch may
be optimized in the future, resulting in greater power of the
mismatch-based thrombolysis studies. For example, we con-
sidered 1.2 as the cutoff for defining a mismatch profile.
However, a post hoc analysis of the DEFUSE study has
recently shown that the highest sensitivity and specificity
occurred at a mismatch ratio of 2.6, suggesting that the
previous studies were probably underpowered and lacked a
sufficiently rigorous definition for the mismatch ratio.27
Furthermore, the 2-second threshold for Tmax is likely also
suboptimal, as a posthoc analyses of DEFUSE data showed a
significantly better correlation between infarct growth and
penumbra salvage volume for perfusion-weighted imaging
lesions defined by Tmax 6 seconds.29 The EPITHET
investigators reported similar findings.33 It is now clear that
both trials included significant volumes of benign oligemia in
their mismatch assessments. Recently, automated online anal-
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ysis of MR mismatch has been described that facilitates rapid
selection of patients for delayed treatment. In summary,
continued refinement in the definitions of different perfusion
parameters may result in a better choice of the best measure
of perfusion (Tmax, time to peak, mean transit time, cerebral
blood volume, or cerebral blood flow) and correction for
arterial input functions.
Thus, the definitions used in the trials published to date
have been generous and have included many patients who
had limited penumbral tissue and limited prospects of clinical
improvement in response to thrombolysis. The recently
formed STIR collaboration is initiating a detailed examina-
tion of this topic. The diversity of mismatch definitions and
large number of investigators involved in these studies
weaken conclusions about the potential value of mismatch in
the future clinical management of patients with stroke.
However, these weaknesses do not extend to our conclusions
about the status of existing evidence for use of thrombolysis
among mismatch patients: patients were selected according to
the best intentions of the investigators under protocols that
were state of the art when written, although they have already
been superseded. Prospective phase III trials are required to
test whether thrombolysis is associated with a favorable
risk/benefit ratio when used under modified circumstances. In
Australia, the EXTEND trial, which will use a phase III
design and randomization of patients 4.5 to 9 hours after
stroke onset to alteplase or placebo and automated mismatch
selection, will test this hypothesis. Meanwhile, although the
concept of selection of patients based on individual patho-
physiology rather than a rigid time window remains attrac-
tive, delayed treatment according to mismatch selection
cannot be recommended as part of routine care until or unless
further trials show benefit.
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Correction
In the article “Mismatch-Based Delayed Thrombolysis: A Meta-Analysis” by Mishra et al,1 two
sentences had incorrect reference citations. The corrections are listed below.
1. On page e27, under Results in the subsection “Literature Search,” 6th line: “(DIAS, 104
patients8; DIAS II, 186 patients18; DEDAS, 37 patients9; DEFUSE, 74 patients10; and
EPITHET, 101 patients11)” should be replaced with “(DIAS, 104 patients20; DIAS II, 186
patients18; DEDAS, 37 patients19; DEFUSE, 74 patients23; and EPITHET, 101 patients22).”
2. On page e28, under the subsection entitled “Did a Favorable Clinical Outcome Occur More
Frequently in the Thrombolyzed Group of Patients?,” 1st line, “With the exception of DIAS
II,24” should be replaced with “With the exception of DIAS II,18.”
The authors and publisher regret these errors.
The corrected version can be viewed online at http://stroke.ahajournals.org.
1[Correction for Vol 41, Number 1, January 2010. Pages e25-e33.]
(Stroke. 2010;41:e399.)
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